U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H18N2O2
Molecular Weight 246.3049
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUNIFIRAM

SMILES

CCC(=O)N1CCN(CC1)C(=O)C2=CC=CC=C2

InChI

InChIKey=DGOWDUFJCINDGI-UHFFFAOYSA-N
InChI=1S/C14H18N2O2/c1-2-13(17)15-8-10-16(11-9-15)14(18)12-6-4-3-5-7-12/h3-7H,2,8-11H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14600801 | https://www.ncbi.nlm.nih.gov/pubmed/18954993 | https://www.ncbi.nlm.nih.gov/pubmed/11087574 | https://www.ncbi.nlm.nih.gov/pubmed/23295391

Sunifiram (DM235) is a piperazine derived research chemical which has anti-amnesiac effects in animal studies. Though Sunifiram is a piracetam derivative, it has a different chemical structure from the racetams and is chemically classed as a piperazine alkaloid. It is known to work in two ways, both as an ampakine that stimulates the activity of glutamine receptors and as a cholinergic that increases the production and release of acetylcholine. Like many nootropics, Sunifiram’s precise mechanisms of action are not entirely understood. However, it is believed that its primary action is that of an ampakine, which means that after crossing the blood-brain barrier it binds to AMPA-type glutamate receptors in the brain. This stimulates the production of glutamate, a vital neurotransmitter that plays the pivotal role in neural activation. Sunifiram is also thought to act as a cholinergic, increasing the production and release of the neurotransmitter acetylcholine. Though the exact process by which this occurs has not been identified, an Italian animal study showed that tests using piperazine compounds such as Sunifiram had a cholinergic effect similar to that of piracetam. No serious side effects of Sunifiram have been documented, but it’s important to remember that no human studies or clinical trials have been conducted.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers.
2006 Spring
Patents

Patents

Sample Use Guides

mice: 0.01–0.1 mg/kg i.p mice: 0.1-1.0 mg/kg p.o.
Route of Administration: Intraperitoneal
Rat hippocampal slices were used for activity evaluation. Slices were superfused with Mg2+-free medium from t = 0 min of superfusion. NBQX was added concomitantly with kynurenate and sunifiram, at t = 30 min till the end of superfusion.
Name Type Language
SUNIFIRAM
Common Name English
1-PROPANONE, 1-(4-BENZOYL-1-PIPERAZINYL)-
Systematic Name English
DM235
Code English
PIPERAZINE, 1-BENZOYL-4-(1-OXOPROPYL)-
Systematic Name English
DM-235
Code English
Code System Code Type Description
WIKIPEDIA
SUNIFIRAM
Created by admin on Sat Dec 16 08:00:30 UTC 2023 , Edited by admin on Sat Dec 16 08:00:30 UTC 2023
PRIMARY
PUBCHEM
4223812
Created by admin on Sat Dec 16 08:00:30 UTC 2023 , Edited by admin on Sat Dec 16 08:00:30 UTC 2023
PRIMARY
EPA CompTox
DTXSID10400996
Created by admin on Sat Dec 16 08:00:30 UTC 2023 , Edited by admin on Sat Dec 16 08:00:30 UTC 2023
PRIMARY
FDA UNII
66924E735K
Created by admin on Sat Dec 16 08:00:30 UTC 2023 , Edited by admin on Sat Dec 16 08:00:30 UTC 2023
PRIMARY
CAS
314728-85-3
Created by admin on Sat Dec 16 08:00:30 UTC 2023 , Edited by admin on Sat Dec 16 08:00:30 UTC 2023
PRIMARY